SVA:TSX, Sernova Biotherapeutics Inc
SVA stock overview
Sernova Biotherapeutics Inc (SVA:TSX) closed at $0.110 on October 23, 2026,
unchanged on the day.
The stock trades 45.0% below its 52-week high of $0.200
and 22.2% above its 52-week low of $0.090.
Over the past year, it lost 35.3%.
Sernova Biotherapeutics Inc is part of the Health Care sector.
Key figures
- Price
- $0.110
- Day change
- 0.00%
- Volume
- 37,444
- Average volume
- 213,879
- Market cap
- 41M+
- 52-week range
- $0.090 – $0.200
- 50-day average
- $0.112
- 200-day average
- $0.142
Price action over the past year
In 252 trading sessions since October 23, 2025, SVA closed higher on 50 days (20%).
Its best day was September 30, 2026 (+22.22%) and its worst was September 14, 2026 (-21.43%).
The stock moved 10% or more in a single session 13 times.
It opened at least 5% above the previous day's high 14 times.
Recent signals
SVA news
-
Oct 19, 2026:
Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics
-
Oct 5, 2026:
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
-
Sep 25, 2026:
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
-
Sep 11, 2026:
Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.
-
Sep 10, 2026:
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
-
Sep 8, 2026:
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
-
Aug 26, 2026:
Cell Encapsulation Global Market Report 2026-2035 | Features Strategic Profiles of Beta-Cell, Betalin Therapeutics, Beta-O2 Technologies, Diatranz Otsuka, Neurotech, Semma Therapeutics, Sernova, ViaCyte
About Sernova Biotherapeutics Inc
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. It develops a commercially-viable treatment for insulin-dependent human diabetes and other metabolic, blood, and neurological diseases with therapeutic cells placed into its implanted, prevascularized and scalable medical device.
Similar stocks
Find more stocks like SVA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.